Annovis Bio: A Speculative Buy For Their Novel Alzheimer’s Disease Treatment – Seeking Alpha

Related Articles:

• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• ANVS401 Improves Colonic Motility in Mouse Models of Early Parkinson’s April 28, 2020 Investigational therapy ANVS401 (also known as Posiphen) reversed gastrointestinal dysfunction linked to early Parkinson’s in two mouse models of the disease. Results of the study, “Translational inhibition of α-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice,” were published in the American Journal of Neurodegenerative Disease. Parkinson’s disease is characterized by aggregates of alpha-synuclein in the nervous system, particularly in dopamine-producing neurons in the…
• Annovis Given US Patent for Potential Parkinson’s Treatment Expected to Enter Phase 2 Trial February 24, 2020 Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma, expects that multiple patents for ANVS401 will be generated from this patent family, each independent and…
• Annovis Given US Patent for Potential Parkinson’s Treatment Expected to Enter Phase 2 Trial February 24, 2020 Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma, expects that multiple patents for ANVS401 will be generated from this patent family, each independent and…
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – November 2019 November 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly research review – October 2019 October 31, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• DNA repair: Alpha synuclein to the rescue September 10, 2019   For the last 21 years, the protein alpha synuclein has developed a reputation as public enemy #1 in the world of Parkinson’s. Tiny errors in the DNA that provides the instructions from making the alpha synuclein protein were found to be the first genetic risk factor for the condition, and then the protein itself was found to be present…
• Bayer doubles down on Parkinson’s? December 10, 2020 # # # # News today of two biotech companies merging did not cause much of a ripple in the media, but the wider implications of the move are rather significant for Parkinson’s. Today it was announced that Brain Neurotherapy Bio (BNB) is going to merge with Asklepios Biopharmaceutical (aka AskBio). BNB are currently clinically testing a GDNF gene therapy…
• Differentiating PD from MSA February 20, 2020   There is a lot of clinical and biological similarities between the neurodegenerative conditions of Parkinson’s and multiple systems atrophy (or MSA). Recently, however, researchers have published a report suggesting that these two conditions may be differentiated from each other using a technique analysing protein in the cerebrospinal fluid – the liquid surrounding the brain, that can be accessed via…
• Probiotics: Food for worms? January 24, 2020     There is a lot of research currently being conducted that is exploring the relationship between the gastrointestinal system and Parkinson’s. A growing body of data suggests that the bacteria in our guts may be having an infuential role. Recently researchers at the University of Edinburgh in Scotland have published the results of a study in which they used…
• That time APOE met Alpha Syn February 10, 2020    Recently two independent research groups published scientific papers providing evidence that a genetic variation associated with Alzheimer’s may also be affecting the severity of pathology in Parkinson’s. The genetic variation associated with Alzheimer’s occurs in a gene (a functional region of DNA) called ApoE, and the Parkinson’s pathology involves the clustering of a protein called alpha synuclein. Specifically, both…
• Man’s best friend August 15, 2019   Recently it has been determined that many people with Parkinson’s have a distinct smell. It is a subtle odour that only some individuals with a very sensitive sense of smell can detect (Click here to read a previous SoPD post on this topic). This curious discovery has given rise to a number of interesting research programmes which are trying…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Viva Las Vagus August 20, 2019   Increasing preclinical evidence is being presented that suggests the gastrointestinal system can play a role in models of Parkinson’s. In addition, there is mounting epidemiological data indicating that the gut can have some kind of influence in people with the condition. Recently, a new paper was published which explores the involvement of the vagus nerve. This is the bundle…
• Monthly Research Review: Jaunary 2020 January 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
• Annovis Bio Showcases its Unique Approach to Alzheimer's at the New York Academy of Sciences - GlobeNewswire December 15, 2020 Annovis Bio Showcases its Unique Approach to Alzheimer's at the New York Academy of Sciences  GlobeNewswire
• QR Pharma Adopts new Corporate Name: Annovis Bio - GlobeNewswire June 24, 2019 QR Pharma Adopts new Corporate Name: Annovis Bio  GlobeNewswireBERWYN, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- QR Pharma, Inc., a biopharmaceutical company developing novel therapies for the treatment of ...
• Annovis Appoints Jeffrey McGroarty Chief Financial Officer - Yahoo Finance July 9, 2019 Annovis Appoints Jeffrey McGroarty Chief Financial Officer  Yahoo FinanceAnnovis Bio, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer's, Parkinson's and other neurodegenerative diseases, ...
• Annovis Appoints Jeffrey McGroarty Chief Financial Officer - GlobeNewswire July 9, 2019 Annovis Appoints Jeffrey McGroarty Chief Financial Officer  GlobeNewswireBERWYN, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a biopharmaceutical company developing novel therapies for the treatment of ...